Recombinant interferon alfa-2b

Phase 3

Recombinant interferon alfa-2b is one of 12 therapeutic programs targeting Malignant Melanoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Malignant MelanomaActive, not recruiting

Neuroendocrine TumorActive, not recruiting

Malignant MelanomaPhase 2

Active, not recruiting

Neuroendocrine TumorPhase 3

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Neuroendocrine Tumor

#DrugCompanyPhaseTrials

Lutathera

AAdvanced Accelerator Applications

Approved

1 2

Avastin

Roche

Phase 3

1 3

Sandostatin

Sun Pharmaceutical Industries, Inc.

Phase 3

1 4

Votrient

Novartis

Phase 2

1 5

Recombinant Human GM-CSF

EEastern Cooperative Oncology Group

Phase 3

1 6

Recombinant interferon alfa-2b

SSt. Jude Children's Research Hospital

Phase 3

1 7

Alphamedix

OOrano Med LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Clinical Stage III Cutaneous Melanoma AJCC V8

NCT02506153

Phase 3Active, not recruiting

Neuroendocrine Tumor

NCT00569127

Phase 3Active, not recruiting

Melanoma of Unknown Primary

NCT01274338

Q2 2031

Phase 2Active, not recruiting

Malignant Melanoma

NCT00539591

Clinical

Trials by Indication[1]

Melanoma of Unknown Primary1 trial

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT01274338·1,673 enrolled

Clinical Stage III Cutaneous Melanoma AJCC v81 trial

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02506153·1,301 enrolled

Neuroendocrine Tumor1 trial

Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT00569127·427 enrolled

Recurrent Melanoma1 trial

A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01708941·88 enrolled

Malignant Melanoma1 trial

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT00539591·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Recombinant interferon alfa-2b. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Recombinant interferon alfa-2b. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSt. Jude Children's Research Hospital

Recombinant interferon alfa-2b

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2031

Trials by Indication[1]

Melanoma of Unknown Primary1 trial

Clinical Stage III Cutaneous Melanoma AJCC v81 trial

Neuroendocrine Tumor1 trial

Recurrent Melanoma1 trial

Malignant Melanoma1 trial

References

Drug Info

Quick Facts

Related News